ZYME- Zymeworks Inc.

Name: Zymeworks Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Zymeworks Inc. (ZYME) has 14 insiders with recent SEC Form 4 filings, including 4 buys and 10 sells. ZYME is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Galbraith Kenneth	257.3K	$6.35M	-
CFO	Stafford Kristin	178.0K	$4.39M	-
COO	Hollywood Mark	66.0K	$1.63M	-
Other	Moore Paul Andrew	58.1K	$1.43M	-
VP	Smith Jeffrey T L	36.0K	$888.7K	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 12, 2026	Hollywood Mark	EVP &Chief Operating Officer	Sale+OE	6,120	$22.67	$138,761.82	-4.4%	+13.6%	-
Jan 12, 2026	Smith Jeffrey T L	EVP &Chief Medical Officer	Sale+OE	9,310	$22.67	$211,090.29	-25.8%	+13.6%	-
Jan 12, 2026	Galbraith Kenneth	Chair &CEO	Sale+OE	30,424	$22.67	$689,818.56	-11.8%	+13.6%	-
Jan 12, 2026	Moore Paul Andrew	Chief Scientific Officer	Sale+OE	9,560	$22.67	$216,758.66	-16.5%	+13.6%	-
Jan 5, 2026	Smith Jeffrey T L	EVP &Chief Medical Officer	Sale+OE	10,538	$25.10	$264,471.13	-36.5%	+1.4%	-
Jan 5, 2026	Galbraith Kenneth	Chair &CEO	Sale+OE	54,343	$25.10	$1,363,840.84	-13.4%	+1.4%	-
Jan 5, 2026	Moore Paul Andrew	Chief Scientific Officer	Sale+OE	20,110	$25.10	$504,698.66	-21.9%	+1.4%	-
Dec 22, 2025	Galbraith Kenneth	Chair &CEO	Sale+OE	47,528	$27.02	$1,284,311.12	-26.3%	-13.0%	-
May 19, 2025	Ecor1 Capital, LLC76	Director, 10% Owner	Buy	55,421	$11.47	$635,585.71	+0.2%	+18.9%	-
Apr 17, 2025	Ecor1 Capital, LLC76	Director, 10% Owner	Buy	128,713	$11.32	$1,456,407.88	+0.4%	+17.3%	-

Page 1Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC